dc.contributor
Institut Català de la Salut
dc.contributor
[Loscertales J] Hematology Department, Hospital Universitario de la Princesa, Madrid, Spain. [Abrisqueta-Costa P] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Gutierrez A] Hematology Department, Hospital Son Espases/IdISBa, Palma de Mallorca, Spain. [Hernández-Rivas JÁ] Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain. [Andreu-Lapiedra R] Hematology Department, Hospital Universitario La Fe, Valencia, Spain. [Mora A] Hematology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Loscertales, Javier
dc.contributor.author
Hernandez-Rivas, Jose-Angel
dc.contributor.author
Andreu-Lapiedra, Rafael
dc.contributor.author
Mora, Alba
dc.contributor.author
GUTIERREZ, ANTONIO
dc.contributor.author
Abrisqueta, Pau
dc.date.accessioned
2025-10-24T10:33:45Z
dc.date.available
2025-10-24T10:33:45Z
dc.date.issued
2023-09-01T07:28:38Z
dc.date.issued
2023-09-01T07:28:38Z
dc.date.issued
2023-08-10
dc.identifier
Loscertales J, Abrisqueta-Costa P, Gutierrez A, Hernández-Rivas JÁ, Andreu-Lapiedra R, Mora A, et al. Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study. Cancers. 2023 Aug 10;15(16):4047.
dc.identifier
https://hdl.handle.net/11351/10202
dc.identifier
10.3390/cancers15164047
dc.identifier.uri
https://hdl.handle.net/11351/10202
dc.description.abstract
Artificial intelligence; Chronic lymphocytic leukemia; Natural language processing
dc.description.abstract
Inteligencia artificial; Leucemia linfocítica crónica; Procesamiento del lenguaje natural
dc.description.abstract
Intel·ligència artificial; Leucèmia limfocítica crònica; Processament del llenguatge natural
dc.description.abstract
The SRealCLL study aimed to obtain real-world evidence on the clinical characteristics and treatment patterns of patients with chronic lymphocytic leukemia (CLL) using natural language processing (NLP). Electronic health records (EHRs) from seven Spanish hospitals (January 2016–December 2018) were analyzed using EHRead® technology, based on NLP and machine learning. A total of 534 CLL patients were assessed. No treatment was detected in 270 (50.6%) patients (watch-and-wait, W&W). First-line (1L) treatment was identified in 230 (43.1%) patients and relapsed/refractory (2L) treatment was identified in 58 (10.9%). The median age ranged from 71 to 75 years, with a uniform male predominance (54.8–63.8%). The main comorbidities included hypertension (W&W: 35.6%; 1L: 38.3%; 2L: 39.7%), diabetes mellitus (W&W: 24.4%; 1L: 24.3%; 2L: 31%), cardiac arrhythmia (W&W: 16.7%; 1L: 17.8%; 2L: 17.2%), heart failure (W&W 16.3%, 1L 17.4%, 2L 17.2%), and dyslipidemia (W&W: 13.7%; 1L: 18.7%; 2L: 19.0%). The most common antineoplastic treatment was ibrutinib in 1L (64.8%) and 2L (62.1%), followed by bendamustine + rituximab (12.6%), obinutuzumab + chlorambucil (5.2%), rituximab + chlorambucil (4.8%), and idelalisib + rituximab (3.9%) in 1L and venetoclax (15.5%), idelalisib + rituximab (6.9%), bendamustine + rituximab (3.5%), and venetoclax + rituximab (3.5%) in 2L. This study expands the information available on patients with CLL in Spain, describing the diversity in patient characteristics and therapeutic approaches in clinical practice.
dc.description.abstract
This study was founded by AstraZeneca Farmacéutica Spain, S.A.
dc.format
application/pdf
dc.format
application/pdf
dc.relation
Cancers;15(16)
dc.relation
https://doi.org/10.3390/cancers15164047
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Leucèmia limfocítica crònica - Tractament
dc.subject
Tractament del llenguatge natural (Informàtica)
dc.subject
Històries clíniques - Informàtica
dc.subject
DISEASES::Hemic and Lymphatic Diseases::Lymphatic Diseases::Lymphoproliferative Disorders::Leukemia, Lymphoid::Leukemia, B-Cell::Leukemia, Lymphocytic, Chronic, B-Cell
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Data Collection::Records::Medical Records::Medical Records Systems, Computerized::Electronic Health Records
dc.subject
INFORMATION SCIENCE::Information Science::Computing Methodologies::Algorithms::Artificial Intelligence::Natural Language Processing
dc.subject
ENFERMEDADES::enfermedades hematológicas y linfáticas::enfermedades linfáticas::trastornos linfoproliferativos::leucemia linfoide::leucemia de células B::leucemia linfocítica crónica de células B
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::recopilación de datos::registros::registros médicos::sistemas informatizados de historias clínicas::historias clínicas electrónicas
dc.subject
CIENCIA DE LA INFORMACIÓN::Ciencias de la información::metodologías computacionales::algoritmos::inteligencia artificial::procesamiento del lenguaje natural
dc.title
Real-World Evidence on the Clinical Characteristics and Management of Patients with Chronic Lymphocytic Leukemia in Spain Using Natural Language Processing: The SRealCLL Study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
